Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 30;16(11):2080.
doi: 10.3390/cancers16112080.

Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies

Affiliations
Review

Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies

Ahmed M Mahmoud et al. Cancers (Basel). .

Abstract

Prostate cancer lung metastasis represents a clinical conundrum due to its implications for advanced disease progression and the complexities it introduces in treatment planning. As the disease progresses to distant sites such as the lung, the clinical management becomes increasingly intricate, requiring tailored therapeutic strategies to address the unique characteristics of metastatic lesions. This review seeks to synthesize the current state of knowledge surrounding prostate cancer metastasis to the lung, shedding light on the diverse array of clinical presentations encountered, ranging from subtle radiological findings to overt symptomatic manifestations. By examining the diagnostic modalities utilized in identifying this metastasis, including advanced imaging techniques and histopathological analyses, this review aims to provide insights into the diagnostic landscape and the challenges associated with accurately characterizing lung metastatic lesions in prostate cancer patients. Moreover, this review delves into the nuances of therapeutic interventions employed in managing prostate cancer lung metastasis, encompassing systemic treatments such as hormonal therapies and chemotherapy, as well as metastasis-directed therapies including surgery and radiotherapy.

Keywords: lung metastasis; metastasis-directed therapy; prostate cancer; systemic therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram of the study selection.

Similar articles

Cited by

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J. Clin. 2023;73:17–48. doi: 10.3322/caac.21763. - DOI - PubMed
    1. Goodman O.B., Flaig T.W., Molina A., Mulders P.F.A., Fizazi K., Suttmann H., Li J., Kheoh T., de Bono J.S., Scher H.I. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:34–39. doi: 10.1038/pcan.2013.41. - DOI - PMC - PubMed
    1. Schymura M.J., Sun L., Percy-Laurry A. Prostate cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: A review of SEER data for 2004–2010. Cancer. 2014;120((Suppl. 23)):3758–3770. doi: 10.1002/cncr.29052. - DOI - PubMed
    1. Scosyrev E., Messing E.M., Mohile S., Golijanin D., Wu G. Prostate cancer in the elderly: Frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012;118:3062–3070. doi: 10.1002/cncr.26392. - DOI - PubMed